PML and myeloid sarcoma: Therefore, we hypothesized that distinct disease-susceptible HLA class II alleles between Caucasian and Japanese patients with MS are associated with differences in JCV clearance and anti-JCV antibody serostatus, which may in part be related to the difference in risk for fingolimod-PML between Caucasian and Japanese patients.